myTomorrows: Interview With CEO Dr. Michel van Harten About Clinical Trials, Expanded Access, And The Future Of Health Tech

▤ Summary

This article profiles myTomorrows CEO Dr. Michel van Harten and explains how the company helps patients and physicians access pre-approval treatments. It highlights the platform’s core capabilities, including clinical trial recruitment, expanded access management, real-world data support, and AI-driven trial matching. The piece also covers the company’s growth, including partnerships with pharmaceutical clients and a €25 million growth equity investment from Avego Healthcare Capital. The interview emphasizes product evolution, regulatory compliance, and the company’s goal of becoming a default gateway for pre-approval therapies.

▦ Linked Companies

myTomorrows

$10M to $25M